131 related articles for article (PubMed ID: 10521418)
1. Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity.
Abe K; Whitehead IP; O'Bryan JP; Der CJ
J Biol Chem; 1999 Oct; 274(43):30410-8. PubMed ID: 10521418
[TBL] [Abstract][Full Text] [Related]
2. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
3. Vav2 is an activator of Cdc42, Rac1, and RhoA.
Abe K; Rossman KL; Liu B; Ritola KD; Chiang D; Campbell SL; Burridge K; Der CJ
J Biol Chem; 2000 Apr; 275(14):10141-9. PubMed ID: 10744696
[TBL] [Abstract][Full Text] [Related]
4. Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity.
Palmby TR; Abe K; Der CJ
J Biol Chem; 2002 Oct; 277(42):39350-9. PubMed ID: 12177050
[TBL] [Abstract][Full Text] [Related]
5. Regulation of proto-Dbl by intracellular membrane targeting and protein stability.
Vanni C; Mancini P; Gao Y; Ottaviano C; Guo F; Salani B; Torrisi MR; Zheng Y; Eva A
J Biol Chem; 2002 May; 277(22):19745-53. PubMed ID: 11907027
[TBL] [Abstract][Full Text] [Related]
6. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential.
Katzav S; Cleveland JL; Heslop HE; Pulido D
Mol Cell Biol; 1991 Apr; 11(4):1912-20. PubMed ID: 2005887
[TBL] [Abstract][Full Text] [Related]
7. Autoinhibition mechanism of proto-Dbl.
Bi F; Debreceni B; Zhu K; Salani B; Eva A; Zheng Y
Mol Cell Biol; 2001 Mar; 21(5):1463-74. PubMed ID: 11238883
[TBL] [Abstract][Full Text] [Related]
8. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
[TBL] [Abstract][Full Text] [Related]
9. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
Crespo P; Bustelo XR; Aaronson DS; Coso OA; Lopez-Barahona M; Barbacid M; Gutkind JS
Oncogene; 1996 Aug; 13(3):455-60. PubMed ID: 8760286
[TBL] [Abstract][Full Text] [Related]
10. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
11. N-terminally truncated Vav induces the formation of depolymerization-resistant actin filaments in NIH 3T3 cells.
Kranewitter WJ; Gimona M
FEBS Lett; 1999 Jul; 455(1-2):123-9. PubMed ID: 10428485
[TBL] [Abstract][Full Text] [Related]
12. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
Groysman M; Nagano M; Shaanan B; Katzav S
Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Vav proteins by intramolecular events.
Bustelo XR
Front Biosci; 2002 Jan; 7():d24-30. PubMed ID: 11779690
[TBL] [Abstract][Full Text] [Related]
14. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins.
Movilla N; Bustelo XR
Mol Cell Biol; 1999 Nov; 19(11):7870-85. PubMed ID: 10523675
[TBL] [Abstract][Full Text] [Related]
15. Requirement for C-terminal sequences in regulation of Ect2 guanine nucleotide exchange specificity and transformation.
Solski PA; Wilder RS; Rossman KL; Sondek J; Cox AD; Campbell SL; Der CJ
J Biol Chem; 2004 Jun; 279(24):25226-33. PubMed ID: 15073184
[TBL] [Abstract][Full Text] [Related]
16. Vav, a GDP/GTP nucleotide exchange factor, interacts with GDIs, proteins that inhibit GDP/GTP dissociation.
Groysman M; Russek CS; Katzav S
FEBS Lett; 2000 Feb; 467(1):75-80. PubMed ID: 10664460
[TBL] [Abstract][Full Text] [Related]
17. Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity.
Yabana N; Shibuya M
Oncogene; 2002 Oct; 21(50):7720-9. PubMed ID: 12400014
[TBL] [Abstract][Full Text] [Related]
18. The VAV family of signal transduction molecules.
Bustelo XR
Crit Rev Oncog; 1996; 7(1-2):65-88. PubMed ID: 9109498
[TBL] [Abstract][Full Text] [Related]
19. Structural determinants for the biological activity of Vav proteins.
Zugaza JL; López-Lago MA; Caloca MJ; Dosil M; Movilla N; Bustelo XR
J Biol Chem; 2002 Nov; 277(47):45377-92. PubMed ID: 12228230
[TBL] [Abstract][Full Text] [Related]
20. Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation.
Bustelo XR; Crespo P; López-Barahona M; Gutkind JS; Barbacid M
Oncogene; 1997 Nov; 15(21):2511-20. PubMed ID: 9399639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
